Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Bottom Line: Decreased ctDNA level in response to the initiation of EGFR-TKI was observed in 4 of 6 eligible patients.In another patient, the T790M ctDNA represented cell subpopulations that respond to cytotoxic agents differently from the major population.Considering the high incidence, ctDNA could be a clinical parameter to complement information from image analyses.
Affiliation: Department of Thoracic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.Show MeSH
Related in: MedlinePlus
Mentions: We compared the distributions of the PM scores with the non‐PD and PD “mutation‐positive in plasma” samples (Fig. 1). The PD samples tended to be distributed in fractions of high PM scores compared with non‐PD samples.
Affiliation: Department of Thoracic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.